Just Released: The 5 Best Stocks to Buy in December 2022 [PREMIUM PICKS]

Premium content from Motley Fool Stock Advisor Canada “Best Buys Now” Pick #1: AbCellera (NASDAQ:ABCL) AbCellera Biologics (NASDAQ:ABCL) develops antibodies to …

| More on:
Piggy bank wrapped in Christmas string lights

Source: Getty Images

Premium content from Motley Fool Stock Advisor Canada

“Best Buys Now” Pick #1:

AbCellera (NASDAQ:ABCL)

AbCellera Biologics (NASDAQ:ABCL) develops antibodies to treat infectious diseases. Its AI-powered technology decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

After nearly touching $15 last month, AbCellera has declined by 24%, and it’s once again at a price where I feel you’re getting all the potential long-term returns at an attractive price. If you’re looking for why the shares have fallen of late, I think it’s most likely because AbCellera’s sales over the last couple of quarters have been weaker than they were over the previous two quarters.

In my view, the current sales were always gravy and not the real story. These sales come almost entirely —there are some research fees included for hitting milestones — from the sales of two COVID-19 treatments developed in conjunction with Eli Lilly (NYSE:LLY); one remains the only approved treatment that is effective against both the current dominant covid strains and past ones.

Our thesis for AbCellera is that these sales are bound to decline over time and are mostly about providing a source of capital to fund the expansion of the business without diluting shareholders. The cash from these sales has actually proven a little more valuable because it has allowed AbCellera to invest in the development of several drug candidates alongside partners with the opportunity to have partial ownership — and a share of the profits — if these drugs get regulatory approval.

The extra cash in the bank has also given AbCellera the financial strength to hold firm on higher royalty rates on the conventional research work done for clients. In short, the long-term benefits of a strong balance sheet have made an already attractive royalty model even more compelling.

The long-term revenue potential continues to get more attractive, too. As of the end of the third quarter, AbCellera had 164 programs under contract with 38 unique clients. That’s 23 more than it had a year ago. During the last quarter, work started on four new programs and all four were for products where AbCellera would get a royalty if the research work leads to commercial treatments. Finally, one more product entered phase one of clinical trials during the quarter, giving AbCellera seven products currently in testing.

If you’re still worried about a dry period before revenue from these new drugs kick in, the company had some good news here, too. While its testing shows the current treatments it developed with Eli Lilly do not work against the two emerging strains of covid, it has identified a modified compound with Eli Lilly that does work. So, there is still a chance that the covid sales stream continues as the rest of the business grows.

With nearly $900 million in cash and no debt, ongoing sales of COVID-19 treatments, better terms getting negotiated on new research contracts, and more candidates entering clinical trials the long-term potential of AbCellera remains very bright.

Nathan Parmelee has positions in AbCellera Biologics. The Motley Fool has positions in and recommends AbCellera Biologics.

“Best Buys Now” Pick #2:

Redacted

logo

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Investing

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »

Businessman holding AI cloud
Tech Stocks

Could Investing $20,000 in Nvidia Make You a Millionaire?

Nvidia stock has made investors millionaires in the last 10 years. Is it too late to invest to become a…

Read more »

Engineers walk through a facility.
Dividend Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

AtkinsRéalis (TSX:ATRL) is one TSX stock I'd never invest in.

Read more »

money cash dividends
Stocks for Beginners

Have $500? 3 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

If you're looking for cheap stocks, these three have a huge future ahead of them, all while costing far less…

Read more »